

## **ANNEX I**

### **SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Recocam 20 mg/ml solution for injection for cattle, pigs and horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One ml contains:

### **Active substance:**

Meloxicam                      20 mg

### **Excipient:**

Ethanol                        150 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Cattle, pigs and horses.

### **4.2 Indications for use, specifying the target species**

#### Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

#### Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

#### Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### **4.3 Contraindications**

See also section 4.7.

Do not use in horses less than 6 weeks of age.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipient(s).

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **4.4 Special warnings for each target species**

None.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain.

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

##### Pregnancy and lactation:

##### **Cattle and pigs:**

Can be used during pregnancy and lactation.

**Horses:**

Do not use in pregnant or lactating mares.

**4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

**4.9 Amounts to be administered and administration route**Cattle

Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs

Single intramuscular injection at a dose of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Horses

Single intravenous injection at a dose of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo-skeletal disorders, oral suspensions of meloxicam may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Avoid introduction of contamination during use.

Do not breach the stopper more than 50 times.

**4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose, symptomatic treatment should be initiated.

**4.11 Withdrawal periods****Cattle:**

Meat and offal: 15 days

Milk: 5 days

**Pigs:**

Meat and offal: 5 days

**Horses:**

Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams)

ATCvet code: QM01AC06

## 5.1 Pharmacodynamic properties

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

## 5.2 Pharmacokinetic particulars

### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg, C<sub>max</sub> values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a C<sub>max</sub> value of 1.9 µg/ml was reached after 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours.

Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Ethanol 99.9%

Anhydrous citric acid

Poloxamer 188

Meglumine

Glycine

Macrogol 300

Sodium hydroxide (for pH adjustment)

Hydrochloric acid (for pH adjustment)

Water for injections

## **6.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after first opening the immediate packaging: 28 days

## **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

## **6.5 Nature and composition of immediate packaging**

Pack size of 1 Type I clear glass vial with Teflon coated bromobutyl rubber stoppers and sealed with an aluminium flip-off tear-off seal. Vials contain 10 ml, 50 ml, 100 ml or 250 ml.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited,  
2, 3 & 4 Airtown Close,  
Tallaght, Dublin 24,  
Ireland.

Tel: +353 (0)1 4515011

Fax: +353 (0)1 4621859

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/133/001-004

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 13/09/2011

Date of last renewal: 09/08/2016

## **10 DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLS**

## A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

### Name and address of the manufacturer responsible for batch release

Bimeda Animal Health Limited,  
2, 3 & 4 Airton Close,  
Tallaght,  
Dublin 24,  
Ireland.

## B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

- Conditions or restrictions regarding supply and use imposed on the marketing authorisation holder

Veterinary medicinal product subject to prescription

- Conditions or restrictions with regard to the safe and effective use of the medicinal product

Not applicable

- Other conditions

Pharmacovigilance system

The MAH must ensure that the system of pharmacovigilance, as described in Part 1 of the marketing authorisation application, is in place and functioning before and whilst the product is on the market.

## C. STATEMENT OF THE MRLS

The active substance in Recocam 20 mg/ml solution for injection for cattle, pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:

Pharmaco-logically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Meloxicam	Meloxicam	Bovine, caprine, porcine, rabbit, <i>Equidae</i>	20 µg/kg 65 µg/kg 65 µg/kg	Muscle Liver Kidney	No entry	Anti-inflammatory agents/Non-steroidal anti-inflammatory agents
		Bovine, caprine	15 µg/kg	Milk		

The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No. 37/2010 indicates that no MRLs are required.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard Box: 10 ml, 50 ml, 100 ml or 250 ml vials

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Recocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

1 x 10 ml  
1 x 50 ml  
1 x 100 ml  
1 x 250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Cattle:** SC, IV

**Pigs:** IM

**Horses:** IV

Read the package leaflet before use.

Do not broach the stopper more than 50 times.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):

**Cattle:** meat and offal: 15 days; milk: 5 days

**Pigs:** meat and offal: 5 days

**Horses:** meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life after first opening the container: 28 days

Once broached, use by ....

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read the package leaflet

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited,  
2, 3 & 4 Airtown Close,  
Tallaght, Dublin 24,  
Ireland.

Tel: +353 (0)1 4515011

Fax: +353 (0)1 4621859

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/133/001 (10 ml)

EU/2/11/133/002 (50 ml)

EU/2/11/133/003 (100 ml)

EU/2/11/133/004 (250 ml)

**17. MANUFACTURER'S BATCH NUMBER**

LOT {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS**

Glass vial label for 50 ml, 100 ml and 250 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Recocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

1 x 50 ml  
1 x 100 ml  
1 x 250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Cattle:** SC, IV  
**Pigs:** IM  
**Horses:** IV

Read the package leaflet before use.  
Do not broach more than 50 times.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):

**Cattle:** meat and offal: 15 days; milk: 5 days

**Pigs:** meat and offal: 5 days

**Horses:** meat and offal: 5 days.  
Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life after first opening the container: 28 days

Once broached, use by ....

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited,  
2, 3 & 4 Airtown Close,  
Tallaght, Dublin 24,  
Ireland.

Tel: +353 (0)1 4515011

Fax: +353 (0)1 4621859

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/133/002 (50 ml)

EU/2/11/133/003 (100 ml)

EU/2/11/133/004 (250 ml)

**17. MANUFACTURER'S BATCH NUMBER**

LOT {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****Glass vial label for 10 ml****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Recocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 20 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml

**4. ROUTE(S) OF ADMINISTRATION**

**Cattle:** SC, IV

**Pigs:** IM

**Horses:** IV

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):

**Cattle:** meat and offal: 15 days; milk: 5 days

**Pigs:** meat and offal: 5 days

**Horses:** meat and offal: 5 days. Not authorised to use in horses producing milk for human consumption.

**6. BATCH NUMBER**

LOT {number}

**7. EXPIRY DATE**

EXP {month/year}

Shelf-life after first opening the container: 28 days

Once broached, use by ....

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET**  
**Recocam 20 mg/ml solution for injection for cattle, pigs and horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Bimeda Animal Health Limited,  
2, 3 & 4 Airtown Close,  
Tallaght, Dublin 24,  
Ireland.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Recocam 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains:

**Active substance:**

Meloxicam                      20 mg

**Excipient:**

Ethanol 99.9%                150 mg

Clear, yellow solution

**4. INDICATION(S)**

Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.  
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.  
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.  
For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.  
For the relief of pain associated with equine colic.

**5. CONTRAINDICATIONS**

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.  
Do not use in horses producing milk for human consumption.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

## **6. ADVERSE REACTIONS**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cattle, pigs and horses

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### Pigs

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

### Horses

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders, oral suspensions of meloxicam may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.  
Do not broach the stopper more than 50 times.

## **10. WITHDRAWAL PERIOD(S)**

**Cattle:** meat and offal: 15 days; milk: 5 days

**Pigs:** meat and offal: 5 days

**Horses:** meat and offal: 5 days

Not authorised for use in horses producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after "EXP". The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain.

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

Interactions with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose, symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>

**15. OTHER INFORMATION**

Pack size of 1 Type I clear glass vial with Teflon coated bromobutyl rubber stoppers and sealed with an aluminium flip-off tear-off seal. Vials contain 10 ml, 50 ml, 100 ml or 250 ml.

Not all pack sizes may be marketed.